RECIST

Also known as: Response Evaluation Criteria In Solid Tumours

The standardised criteria for measuring tumour response on imaging in solid-tumour oncology trials.

Definition

RECIST 1.1 (Response Evaluation Criteria In Solid Tumours) is the international standard for measuring tumour burden change on CT/MRI in solid-tumour trials. Defines complete response (CR), partial response (PR ≥30% shrinkage), stable disease (SD), and progressive disease (PD ≥20% growth or new lesions). Modified RECIST (mRECIST) and iRECIST apply for HCC and immunotherapy respectively.

See also

• ORR — The proportion of patients with a complete or partial tumour response.
• PFS — Time from treatment start until disease progression or death.

Other clinical terms

• Phase 1 trial
• Phase 2 trial
• Phase 3 trial
• Primary endpoint
• Surrogate endpoint
• CDx